ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,883,709 | +31.9% | 290,483 | +49.4% | 0.01% | +42.9% |
| Q2 2023 | $5,977,608 | -18.0% | 194,457 | -3.9% | 0.01% | -22.2% |
| Q1 2023 | $7,289,337 | -8.4% | 202,313 | +0.5% | 0.01% | -10.0% |
| Q4 2022 | $7,956,048 | +3.1% | 201,317 | +5.2% | 0.01% | 0.0% |
| Q3 2022 | $7,720,000 | -10.8% | 191,429 | -7.0% | 0.01% | 0.0% |
| Q2 2022 | $8,651,000 | +32.1% | 205,777 | +22.5% | 0.01% | +66.7% |
| Q1 2022 | $6,547,000 | -1.9% | 168,035 | +0.4% | 0.01% | 0.0% |
| Q4 2021 | $6,671,000 | +19.5% | 167,407 | +8.4% | 0.01% | 0.0% |
| Q3 2021 | $5,583,000 | -6.0% | 154,492 | -0.6% | 0.01% | 0.0% |
| Q2 2021 | $5,940,000 | -11.0% | 155,492 | +1.6% | 0.01% | -14.3% |
| Q1 2021 | $6,674,000 | -9.4% | 152,992 | +3.9% | 0.01% | -22.2% |
| Q4 2020 | $7,367,000 | -32.4% | 147,192 | -43.1% | 0.01% | -40.0% |
| Q3 2020 | $10,892,000 | +18.8% | 258,891 | +37.1% | 0.02% | +15.4% |
| Q2 2020 | $9,171,000 | – | 188,891 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |